Vericel Corp VCEL
Vericel Corp (Nasdaq: VCEL) is a drug developer. Its lead program, MACI (autologous cultured chondrocytes on scaffold), is in Phase 3 for symptomatic knee cartilage defects. Its next catalyst on record is MACI: UK MHRA authorization and commercialization (2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: MACI — UK MHRA authorization and commercialization (2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| MACI / MACI Arthro | knee cartilage defects | cell therapy | Approved |
| Epicel | severe burns (HDE device) | cell therapy | Approved |
| NexoBrid | eschar removal in thermal burns | biologic-other | Approved |
| MACI ankle (MASCOT) | talus cartilage defects | cell therapy | Phase 3 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.